{"doi":"10.1016/j.jinf.2025.106412","title":"Individual patient and donor seroprofiles in convalescent plasma treatment of COVID-19 in REMAP-CAP clinical trial","abstract":null,"journal":"Journal of Infection","year":2025,"id":636766,"datarank":0.24141568686511508,"base_score":1.6094379124341003,"endowment":1.6094379124341003,"self_citation_contribution":0.24141568686511508,"citation_network_contribution":0.0,"self_endowment_contribution":0.24141568686511508,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":4,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1377358,"name":"Richard Mayne","orcid":"0000-0003-1915-4993","position":1,"is_corresponding":false},{"id":1653007,"name":"Chanice Knight","orcid":"0009-0003-1251-4404","position":2,"is_corresponding":false},{"id":1653012,"name":"Hannia L. Almonacid-Mendoza","orcid":null,"position":3,"is_corresponding":false},{"id":1653015,"name":"Shannah Secret","orcid":null,"position":4,"is_corresponding":false},{"id":1653017,"name":"Lise Estcourt","orcid":null,"position":5,"is_corresponding":false},{"id":104935,"name":"Jussi Hepojoki","orcid":"0000-0001-5699-214X","position":6,"is_corresponding":false},{"id":1653019,"name":"Tonći Šuštić","orcid":null,"position":7,"is_corresponding":false},{"id":70569,"name":"Abigail Lamikanra","orcid":"0000-0002-9287-2177","position":8,"is_corresponding":false},{"id":555233,"name":"Hoi Pat Tsang","orcid":null,"position":9,"is_corresponding":false},{"id":317356,"name":"David Menon","orcid":"0000-0002-3228-9692","position":10,"is_corresponding":false},{"id":1552787,"name":"Manu Shankar-Hari","orcid":null,"position":11,"is_corresponding":false},{"id":500503,"name":"C. Ellen van der Schoot","orcid":"0000-0002-8065-3540","position":12,"is_corresponding":false},{"id":308475,"name":"Gestur Vidarsson","orcid":"0000-0001-5621-003X","position":13,"is_corresponding":false},{"id":51478,"name":"David J. Roberts","orcid":"0000-0003-0648-6585","position":14,"is_corresponding":false},{"id":106094,"name":"Peter Simmonds","orcid":"0000-0002-7964-4700","position":15,"is_corresponding":false},{"id":161087,"name":"Klaus Hedman","orcid":"0000-0003-1779-7960","position":16,"is_corresponding":false},{"id":716550,"name":"Heli Harvala","orcid":"0000-0001-9154-4190","position":17,"is_corresponding":false},{"id":161085,"name":"Visa Nurmi","orcid":"0000-0001-8052-5592","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Individual patient and donor seroprofiles in convalescent plasma treatment of COVID-19 in REMAP-CAP clinical trial","abstract":"Objectives Convalescent plasma (CP) treatment of COVID-19 has shown significant therapeutic effect only when administered early. We investigated the importance of patient and CP seroprofiles on treatment outcome in REMAP-CAP CP trial. Methods We evaluated neutralising antibodies (nAb), anti-spike (S) IgM, IgG, IgG avidity, IgG fucosylation and respiratory viral loads in a sub-set of patients (n=80) and controls (n=51) before and after transfusion, comparing them to those in the CP units (n=157) they received. Results Most patients were SARS-CoV-2 seropositive pre-transfusion (72% nAb; 89% S-IgG seropositivity). The majority (80%) had higher pre-transfusion S-IgG levels (median 1.7×10 6 arbitrary units (AU); 56%) or S-IgG production rates (median 1.1×10 6 AU/day; 64%) than they received from CP (median 2.2×10 5 AU). Only 22% of the patients demonstrated significant (median 24-fold) increase in their S-IgG levels acquired from transfusion. Better outcomes, measured by organ support-free days, were associated with increase in S-IgM levels (p=0.007), decreased S-IgG fucosylation (p<0.001), lower patient age (p<0.001) but not with receiving CP (p=0.337). Conclusions Based on our data, increased S-antibody levels linked to transfused CP were only observed in pre-seroconversion or immunodeficient patients lacking their own SARS-CoV-2 antibodies, representing the groups where CP treatment has previously shown most benefit.","is_dataset_classified":null,"base_score":1.6094379124341003,"endowment":1.6094379124341003,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"39798805","pmcid":null,"openalex_id":"https://openalex.org/W4406232217","authors":[],"funders":[{"funder_name":"National Institute for Health and Care Research","grant_id":"COVID-19-RECPLAS","title":null},{"funder_name":"Sigrid Juséliuksen Säätiö","grant_id":"","title":null},{"funder_name":"Finska Läkaresällskapet","grant_id":"","title":null},{"funder_name":"NHS Blood and Transplant","grant_id":"","title":null},{"funder_name":"Magnus Ehrnroothin Säätiö","grant_id":"","title":null},{"funder_name":"Research Council of Finland","grant_id":"","title":null}],"total_grants":6,"fwci":3.1307,"citation_percentile":0.8986964,"influential_citations":0,"citation_trend":[{"year":2025,"count":3},{"year":2026,"count":1}],"oa_status":"gold","license":"cc-by","oa_locations":[{"url":"https://www.journalofinfection.com/article/S0163-4453(25)00006-4/pdf","host_type":"journal"},{"url":"https://www.journalofinfection.com/article/S0163-4453(25)00006-4/pdf","host_type":"GOLD"},{"url":"https://www.journalofinfection.com/article/S0163-4453(25)00006-4/pdf","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S0163445325000064?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S0163445325000064?httpAccept=text/plain","host_type":"publisher"},{"url":"https://doi.org/10.1016/j.jinf.2025.106412","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/39798805","host_type":"repository"},{"url":"https://kclpure.kcl.ac.uk/portal/en/publications/27c1e2c9-decb-4418-9415-90329dad615e","host_type":"repository"},{"url":"https://www.research.ed.ac.uk/en/publications/55f3c247-a098-43a6-813b-c49d4ce38257","host_type":"repository"},{"url":"https://pure.amsterdamumc.nl/en/publications/cbeea01b-f469-4ff3-9451-9226f6329314","host_type":"repository"},{"url":"https://dspace.library.uu.nl/handle/1874/475221","host_type":"repository"},{"url":"https://pure.amsterdamumc.nl/files/143246690/Individual-patient-and-donor-seroprofiles-in-convalescent-plasma-treatment-of-covid-19-in-remap-cap-clinical-trial.pdf","host_type":"repository"}],"fields_of_study":["SARS-CoV-2 and COVID-19 Research","COVID-19 Clinical Research Studies","vaccines and immunoinformatics approaches","Medicine"],"mesh_terms":["COVID-19","SARS-CoV-2","COVID-19 Serotherapy","Adult","Aged","Antibodies, Viral","Blood Donors","Female","Humans","Immunoglobulin G","Immunoglobulin M","Immunization, Passive","Male","Middle Aged","Treatment Outcome","Viral Load","Antibodies, Neutralizing"],"keywords":["Convalescent plasma","Coronavirus disease 2019 (COVID-19)","Medicine","2019-20 coronavirus outbreak","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)","Internal medicine","Virology","Outbreak","Antibodies","Infectious diseases","Serology","Critical Care","Transfusion Medicine","Covid-19","Sars-cov-2","Convalescent Plasma Treatment"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-06T17:42:29.396760Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}